

# LeadAction-Onco Competition

<b>DEADLINES</b>  <b>Submission of Notice of Intent:</b> <b>October 30, 2018, 4:30 p.m.</b>  <b>Submission of Complete Application:</b> <b>February 4, 2019, 4:30 p.m.</b>	<b>For all questions related to the Competition:</b> <b>Program Manager FRQS</b> Manon Pelletier 514 873-2114 extension 1243 <a href="mailto:manon.pelletier@frq.gouv.qc.ca">manon.pelletier@frq.gouv.qc.ca</a>
	<b>For all questions related to IRICoR:</b> <b>Project Manager IRICoR</b> Audrey Segret <a href="mailto:audrey.segret@umontreal.ca">audrey.segret@umontreal.ca</a>
	<b>For all questions related to the Oncopole:</b> <b>Project Manager Oncopole</b> Charles Meunier <a href="mailto:cmeunier@oncopole.ca">cmeunier@oncopole.ca</a>

## COMPETITION PROMOTERS AND CONTEXT

As a project maturation cluster in the field of drug discovery, **IRICoR** is a not-for-profit organization based at the Institute for Research in Immunology and Cancer (IRIC) of Université de Montréal. IRICoR’s mandate is to accelerate the discovery, development and commercialization of novel therapies in cancer, immunotherapy and related fields. Since 2008, IRICoR has successfully combined industry-standard business expertise and cutting-edge research. IRICoR invests in and supports particularly innovative selected projects, ensuring an effective transition of fundamental research into innovative therapies, through either co-development partnerships with the biopharmaceutical industry or the creation of spin-off companies. IRICoR provides selected academic and industry projects with access to its drug discovery network of experts and infrastructure, including one of the largest academia-based medicinal chemistry groups in Canada. IRICoR’s major funding sources for the 2018-2023 period include the Canadian government’s Centres of Excellence for Commercialization and Research (CECR) program, Québec government’s programs through the *Ministère de l’Économie, de la Science et de l’Innovation* (MESI), and collaborative partnerships with the biopharmaceutical industry. The LeadAction-Onco Competition fits in perfectly with IRICoR’s mission. This Competition is a great opportunity for the Centre to continue building a portfolio of high-value oncology and immuno-oncology projects sourced from across Canada and internationally. In this Competition, IRICoR is joining forces with Oncopole, a key oncology player in Québec.

The **Oncopole** is a Québec hub for research, development and investment to accelerate the fight against cancer. Created in February of 2017, it is the product of a unique co-creation process led by the *Fonds de recherche du Québec - Santé* (FRQS) and made possible by an initial \$15M investment from Merck Canada. Oncopole's mission is to act as a catalyst leveraging actions of key players in Québec's oncology and innovation research ecosystem. As a result, it aims to position the province as a leader in the field. Its priorities of action, namely research, entrepreneurship, commercialization and integration of innovation, as well as clinical relevance, are orchestrated in order to foster the mobilization of stakeholders, the discovery of innovative approaches to fight cancer and, ultimately, to generate a positive impact for the benefit of patients.

In keeping with their respective organizational strategies, and in an effort to develop and highlight scientific excellence in oncology on a path towards commercialization of innovative therapeutic solutions, IRICoR and the Oncopole, in partnership with the FRQS <sup>1</sup> («Promoters»), are proud to announce the launch of the LeadAction-Onco Competition (the “Competition”).

## PROJECT AND APPLICANTS ELIGIBILITY

The Competition’s main objective is to provide funding to skilled scientists from Québec and the rest of Canada, whose research work in oncology or in immuno-oncology will lead to developing highly innovative new therapies, with great commercial potential. This will pave the way over the long term for the next generation of therapeutics in oncology.

## PROJECT ELIGIBILITY

<b>Competition objectives</b>	<p>The selected projects must respond to a clearly identified medical need and must pave the way for innovative new treatments that could have a major impact on cancer patients, in order to maximize the socio-economic benefits in both Québec and rest of Canada.</p> <p>Submitted projects do not need to be limited to a particular type of cancer. Furthermore, they can be related to the development of biopharmaceutical compounds or biotherapies in oncology or in immuno-oncology, such as antibodies, oncolytic viruses, small molecules, cell products such as stem cells or T cells, synthetic peptides, and RNA-based approaches. This list is non-exhaustive.</p> <p>The Competition aims to promote translational research work from hit identification to pre-clinical studies. Here are a few examples of fundable activities:</p> <ul style="list-style-type: none"> <li>• <b>Hit identification and hit to lead transition:</b> <ul style="list-style-type: none"> <li>○ High-throughput screening using a previously developed assay or a previously validated method;</li> </ul> </li> </ul>
-------------------------------	---

<sup>1</sup> The FRQS is mandated by IRICoR and the Oncopole to handle the management of the Competition on behalf of the 2 organizations.

- Therapeutic activity analysis of active molecules (stability, solubility, synthesis feasibility of biopharmaceutical compounds);
- Preparation of secondary assays (specificity, selectivity or other).
- **Lead optimization/Pre-clinical studies:**
  - Structure-activity relationship analysis or other optimization allowing to better define the commercial product of interest;
  - Preparation of *in vivo* models and efficacy analysis;
  - Primary pharmacokinetic analyses (pharmacokinetic and toxicity);
  - Other analyses to better define the clinical application.

Please note that within the framework of the Competition, applicants wishing to use drug discovery core facilities should consider the opportunities offered by IRICoR's partner institutions and should contact them when developing their project plan. Québec-based partner institutions include:

- [The Institute for Research in Immunology and Cancer \(IRIC\)-Université de Montréal \(UdeM\);](#)
- [The biopharmacy platform of the Faculty of Pharmacy of the Université de Montréal \(UdeM\);](#)
- [The Goodman Cancer Research Centre \(GCRC\) – McGill University;](#)
- [The Research Institute of the McGill University Health Centre \(RI-MUHC\);](#)
- [The Pharmacology Institute of Sherbrooke \(IPS\);](#)
- [Le Centre de recherche du Centre hospitalier de l'Université de Montréal \(CRCHUM\);](#)
- [Le Centre hospitalier universitaire de Québec – Université Laval;](#)
- [Research Centre – Québec Heart and Lung Institute;](#)
- [The MILA-Institut québécois d'intelligence artificielle.](#)

Canadian partner institutions include the [Lunenfeld-Tanenbaum Research Institute](#). Additional references may be provided upon request to IRICoR.

## APPLICANTS ELIGIBILITY

### Conditions

All individuals from an institution, centre, research institute or department (hereinafter "Institution") affiliated to a Québec university, and associated with the project as a Principal Investigator, as well as Co-Investigators, must meet the definition of one of the following research statutes (see the Definitions section of the [Common General Rules](#)):

- University Researcher

- Clinical University Researcher

The managing Institution is generally the employing Institution of the funding recipient (see Section 6.2 of the Common General Rules).

#### **Research team structure**

The research team must comprise:

- **One (1) Principal Investigator**
- **A maximum of three (3) Co-Investigators**
- **A maximum of four (4) collaborators.**

#### **More specifically:**

- **The Principal Investigator must be from an Institution affiliated to a Québec-based university.**

The Principal Investigator will represent the project, manage the application and the internal scientific direction of the project according to the administrative conditions/requirements of the FRQS (see the [Definitions of the Common General Rules](#) section).

Early career researchers (Junior 1 and Junior 2) are encouraged to submit an application as a Principal Investigator (the Junior status begins no more than six (6) years after obtaining a Ph.D. and lasts no more than eight (8) years).

**Postdoctoral trainees cannot apply to this Competition as Principal Investigators.**

#### **Principal Investigator may complete their team by adding up to:**

- **A maximum of three (3) Co-Investigators (no minimum required).**

The Co-Investigator(s) may be from an Institution affiliated either to a **Québec-based university** or to a **Canada-based (outside Québec) university**.

The Co-Investigator(s) must contribute significantly or provide specific expertise to the research project relating to the funding application.

The Co-Investigator(s) from an Institution affiliated to a **Québec-based university** must meet the requirements of the FRQS (see the [Definitions of the Common General Rules](#) section).

The Co-Investigator(s) from an Institution affiliated to a **Canada-based (outside Québec) university:**

- Must be a university faculty member;
- May be assigned management of part of the funds through a transfer agreement issued by the Québec-based managing Institution for an amount corresponding to no more than the portion of the funds coming from IRICoR (maximum of \$300,000 over 2 years).

**Postdoctoral trainees cannot apply to this Competition as Co-Investigators.**

	<ul style="list-style-type: none"> <li>• A <b>maximum</b> of four (4) collaborators.</li> </ul> <p>The collaborator(s) must meet the definition found in the <a href="#">Definitions of the Common General Rules</a> section.</p> <p>The collaborator(s) must provide specific expertise to the research project related to the funding application. However, he/she/they will not have access to funds from this Competition.</p> <p>Investigators affiliated to federal or provincial laboratories are <u>only eligible as collaborators</u> in this Competition.</p>
<b>Professional Order for Clinical University Researchers in Québec</b>	<p>Individuals with the status of Clinical University Researcher must prove that they are members in good standing of the professional order governing them in Québec, have a valid license to practice in Québec and have professional liability insurance.</p>
<b>Multiple applications</b>	<p>An investigator:</p> <ul style="list-style-type: none"> <li>• May only submit one project to this Call for proposals as a Principal Investigator; and</li> <li>• May participate in a maximum of two (2) projects as a Co-Investigator.</li> </ul> <p>Therefore, an Investigator may participate in a maximum of 3 projects in this Competition.</p>
<b>Employment affiliation and domicile</b>	<p>The Principal Investigator, as well as the Co-Investigators from Québec, must be employed by a managing Institution and be domiciled in Québec at the time the application is submitted (see Section 2.1 of the Common General Rules).</p> <p>Collaborators may be from Québec or from outside Québec, but no funds may be transferred to them.</p>
<b>Ethics</b>	<p>The Principal Investigator and the Co-Investigators from an Institution affiliated to a <b>Québec-based university</b> must comply with ethics regulations (see sections 5.3 and 5.4 of the Common General Rules).</p>
<b>Basic training in research ethics</b>	<p>Basic training in research ethics is mandatory when the research project involves human subjects. Research on human beings involves:</p> <ul style="list-style-type: none"> <li>• Participation of human beings as subjects;</li> <li>• Use of human biological material (parts, products, tissues, cells, genetic material derived from the human body, from a living or deceased person);</li> <li>• Assisted reproduction activities or the use of embryos derived therefrom, within the meaning of the Act respecting clinical and research activities relating to assisted reproduction (R.S.Q. Chapter A-5.01); and/or</li> <li>• Use of administrative, scientific or descriptive data from human beings.</li> </ul>

This basic training consists of successfully completing levels 1 and 3 of the online tutorial set out by the *Ministère de la Santé et des Services sociaux du Québec*. [Didacticiel en ligne](#).

Principal Investigators and Co-Investigators from an Institution, affiliated to a **Québec-based university** must have successfully completed the basic training **before receiving their first payment**.

## REQUIRED DOCUMENTS – NOTICE OF INTENT

The FRQS handles the management of the Competition on behalf of IRICoR and the Oncopole.

**Please note that in cases where the application is drafted in French, IRICoR, through the FRQS, may request that the applicant provide an English translation for evaluation purposes.**

All correspondence with the FRQS may be conducted in French or in English.

### Transmission of documents:

All documents described below must be sent by e-mail to Manon Pelletier, Program Manager at the FRQS ([manon.pelletier@frq.gouv.qc.ca](mailto:manon.pelletier@frq.gouv.qc.ca)).

**Missing documents or documents that do not comply with the Competition rules and forms may result in the file being ineligible.**

No extensions will be permitted. All forms not transmitted within the deadlines indicated will be automatically rejected.

The documents must be integrated into a single (1) PDF document. The Principal Investigator's CV, **including detailed contributions**, should be inserted into the PDF document.

The date and time of the transmission of the e-mail is proof of the date and time of the documents' filing.

### Principal Investigator

**NOTE: The Notice of Intent should be submitted to the FRQS by the Principal Investigator managing the project and must include:**

- Notice of Intent form;
- Canadian Common CV, *Funding CV* version for the FRQS (last update between June, 2016 and the Competition deadline);
- Detailed contributions (last update between June, 2016 and the Competition deadline); consult the "Guidelines for the CV attachment file" available in the toolbox;
- Letter of support from the technology transfer unit (or equivalent entity) to which the Principal Investigator is affiliated, indicating having been made aware of the project submission.

Only investigators whose Notices of Intent were considered to be eligible will be invited to submit a complete application (see the Evaluation section).

The FRQS will send an e-mail confirming the acceptance or rejection of the Notice of Intent to each applicant.

## REQUIRED DOCUMENTS – COMPLETE APPLICATION

### Transmission of documents:

All documents described below must be sent by e-mail to Manon Pelletier, ([manon.pelletier@frq.gouv.qc.ca](mailto:manon.pelletier@frq.gouv.qc.ca)), Program Manager at the FRQS.

**Missing documents or documents that do not comply with the Competition rules and forms may result in the file being ineligible.**

No extensions will be permitted. All forms not transmitted within the deadlines indicated will be automatically rejected.

All documents must be integrated into a single (1) PDF document. The CVs of all Investigators, including the detailed contributions, should be inserted one after the other in the PDF document.

The date and time of the transmission of the e-mail is proof of the date and time of the documents' filing.

<b>Principal Investigator</b>	<p><b>NOTE: The complete application must be submitted to the FRQS by the Principal Investigator of the managing Institution and must include:</b></p> <ul style="list-style-type: none"> <li>• Complete Application form;</li> <li>• Canadian Common CV, <i>Funding CV</i> version for the FRQS (last update between June, 2016 and the Competition deadline);</li> <li>• Detailed contributions (last update between June, 2016 and the Competition deadline); consult the “Guidelines for the CV attachment file” available in the toolbox;</li> <li>• Letter of support from the administrators of the institution or university department in which the Principal Investigator’s research will be carried out, indicating the commitment towards the Principal Investigator and the project;</li> <li>• Letters of support from collaborators, if applicable;</li> <li>• For clinicians: a letter from the director of the clinical department or the dean of the faculty specifying the number of hours for which the applicant will be released from his/her clinical obligations to carry out the research project (only for clinicians who are not recipients of an FRQS career award).</li> <li>• A quote presenting the costs associated with the services to be provided by targeted drug discovery core facilities.</li> </ul>
<p><b>Co-Investigators</b> from an Institution affiliated to a <b>Québec-based university</b></p>	<ul style="list-style-type: none"> <li>• Canadian Common CV, <i>Funding CV</i> version for the FRQS (last update between June, 2016 and the Competition deadline);</li> <li>• Detailed contributions (last update between June, 2016 and the Competition deadline); consult the “Guidelines for the CV attachment file” available in the toolbox;</li> <li>• Letter of support from the administrators of the institution or the university department in which the Co-Investigator’s research will be carried out;</li> </ul>

	<ul style="list-style-type: none"> <li>For clinicians: a letter from the director of the clinical department or the dean of the faculty specifying the number of hours for which the applicant will be released from his/her clinical obligations to carry out the research project (only for clinicians who are not recipients of an FRQS career award).</li> </ul>
<b>Co-Investigators</b> from an Institution affiliated to a <b>Canada-based (outside Québec) university</b>	<ul style="list-style-type: none"> <li>Canadian Common CV or free format CV including the list of the publications most relevant to the project;</li> <li>Letter of support from the administrators of the institution or university department in which the Co-Investigator's research work will be carried out.</li> </ul>

## RESEARCH LOCATION

<b>Choice of the Principal Investigator's research location</b>	An FRQS research center, an institution administered by the <i>Ministère de la Santé et des Services sociaux</i> (MSSS) or a Québec university.
<b>Change of research location</b>	<p>The FRQS expects that the grantee will conduct his/her project at the same institution or university that initially endorsed the application throughout the entire grant period.</p> <p>The grantees who wish to change their research location must submit an official letter of request by e-mail to the FRQS. The request must detail the reasons for the change and describe all possible consequences on the research project.</p> <p>University or institutional authorities must also notify the FRQS in writing once they have approved the change of location.</p> <p>The administration of the new university or institution must also notify the FRQS in writing that they accept to host the grantee.</p>
<b>Choice of the Co-Investigator's research location</b>	<p><b>In Québec:</b> an FRQS research center, an institution administered by the <i>Ministère de la Santé et des Services sociaux</i> (MSSS) or a university.</p> <p><b>In Canada (outside Québec):</b> an institution in the public or parapublic sector, excluding private companies.</p>

## TERM OF THE GRANT

<b>Term</b>	Two (2) years, non-renewable
<b>Funding Start Date</b>	April, 2019

## AMOUNT OF THE GRANT

<b>Amount</b>	<p>The total budget for the Competition is \$2.4M (50% IRICoR – 50% Oncopole).</p> <p>Up to \$600,000 per project for two (2) years, with \$300,000 per project per year.</p>
---------------	---

	<p>For each funded project, a maximum of \$300,000 over two (2) years (maximum of \$150,000 per year) may be allocated to drug discovery activities carried out in Canada (outside Québec). The managing Institution will handle the transfer of funds.</p> <p>Co-funding is not mandatory.</p> <p>Payment of the second year of funding will only take place after evaluation and validation of the achieved deliverables by the LeadAction-Onco Committee (see the Evaluation section for more details).</p> <p>It should be noted that following the end of this Competition funding period, IRICoR may continue to invest in the projects based on their progression and achieved deliverables.</p>
<p><b>Institutions administering the grant</b></p>	<p>The list of institutions that can administer funding from the FRQ is limited to the managing institutions recognized by the FRQ, including mainly universities, CIUSSS, CISSS, some institutions of the healthcare network and colleges.</p> <p>The managing Institution is generally the employing institution of the Principal Investigator (see Section 6.2 of the <a href="#">Common General Rules</a>).</p>
<p><b>Indirect research costs</b></p>	<p>This Competition does not benefit from the amount paid out by FRQS and IRICoR to cover the Institutions' indirect research costs.</p>

**ELIGIBLE EXPENDITURES**

<p><b>Eligible</b></p>	<p>For each eligible expense listed below, please refer to Section 8 of the FRQ Common General Rules:</p> <ul style="list-style-type: none"> <li>• Master's and doctoral awards or scholarships, postdoctoral fellowships and supplements, and, where applicable, salary for graduate students and postdoctoral fellows</li> <li>• Salaries and social benefits of research or coordination associates, research technicians or research assistants;</li> <li>• Research material (including the purchase and housing of animals) and all other expenses required to carry out the research project, conditional upon adequate justification in the application;</li> <li>• Costs related to the use of drug discovery core facilities;</li> <li>• Travel and accommodation costs within the framework of the funded project (up to 1% of the total budget);</li> <li>• Costs related to the acquisition of biological material from biobanks (up to 2% of the total budget);</li> <li>• Expenses related to the protection of intellectual property (filing of patents or licenses).</li> </ul>
------------------------	--

<b>Non eligible</b>	<ul style="list-style-type: none"> <li>• Remuneration of the Principal Investigators, Co-Investigators and collaborators;</li> <li>• Purchase of equipment, costs of leasing (or purchasing) facilities;</li> <li>• Participation in conferences and conventions;</li> <li>• Costs related to organizing knowledge mobilization activities;</li> <li>• Research activities that have already been the subject of funding will not be funded if an award has been previously granted.</li> </ul>
---------------------	---

## EVALUATION

<b>Notice of Intent</b>	<p>The Notice of Intent will be used to determine the Principal Investigators' eligibility. It will also allow the Promoters to evaluate the administrative and scientific eligibility of the grant application in view of the Competition's objectives.</p> <p>The Notice of Intent will enable the Promoters to establish the LeadAction-Onco Review Committee (see below for details). Together with IRICoR and the Oncopole, the FRQS will validate the eligibility of the reviewers selected.</p> <p>Only applicants whose Notices of Intent are deemed eligible will be invited, by e-mail from the FRQS, to submit a complete application.</p>
<b>Complete Application</b>	<p>The Principal Investigator for the grant application, as well as the managing Institution, must remain the same as those for the Notice of Intent.</p> <p>The modification or addition of Co-Investigators and collaborators is permitted.</p>
<b>LeadAction-Onco Review Committee</b>	<p>The complete applications will be evaluated by the LeadAction-Onco Review Committee (hereinafter the "Committee") in plenary session.</p> <p>The Committee will comprise both scientific experts and industry experts from the fields of oncology and immuno-oncology. The scientific members, from outside Québec, will be experts in translational/clinical research.</p> <p>Members from industry will come from the following fields: finance, biopharmaceutical industry, business development and entrepreneurship.</p> <p>The <b>selection</b> of all Committee members will be made in compliance with the FRQS and IRICoR regulations, in line with the Conflict of interest policies and guidelines of both organizations.</p> <p>All projects evaluated by the Committee will be processed with complete confidentiality, in compliance with the policies of the FRQS and IRICoR.</p> <p>Some members of the Committee will also be asked to evaluate the projects at the end of the first and second years of investment.</p>
<b>Evaluation criteria of the Complete Application</b>	<p>Complete Applications will be evaluated according to well-defined criteria and weighting as follows:</p> <ul style="list-style-type: none"> <li>• <b>Project positioning and scientific excellence (20%):</b></li> </ul>

- Context, preliminary results and relevance of problem;
  - Clarity of scientific objectives;
  - Innovative character;
  - Development stage of the project to be funded;
  - Extent of link between target and potential application (e.g., mechanism of action).
- **Scientific and technical feasibility (15%):**
    - Quality of the applied research methodology (rigor in defining biological assays and/or pharmacological models used);
    - Relevance of the technological core facilities used in the project;
    - Identification of risks and mitigation plan;
    - Expected milestones/deliverables: specific, measurable, realistic, and timely.
  - **Experience and expertise of the research team (5%):**
    - Achievements and scientific level of the research team (outreach at the Canadian and/or international level, etc.);
    - Involvement of early career researchers (Junior 1 and Junior 2) (an asset).
  - **Commercial potential (35%):**
    - Market Assessment;
    - Clear unmet medical need;
    - Business opportunity/value creation;
    - Previous discussions with potential private partners.
  - **Competitive environment and intellectual property (20%):**
    - Competitive advantage (direct and indirect) of the project;
    - Positioning and environment of the intellectual property if already generated;
    - Potential for creating new intellectual property.
  - **Detailed budget (5%):**
    - Adequate budget justification in line with the proposed project;
    - Financial leverage (if applicable).

It should be noted that Investigators must consult the technology transfer unit of their Institution or any equivalent structure in order to properly describe the project's potential commercialization strategy in view of the Competition's objectives.

## MANAGEMENT OF THE AWARD AND KNOWLEDGE MOBILIZATION

### Conditions for releasing the allocated funds

If a positive funding decision is made, the Principal Investigator will receive an award letter, with a copy to the managing Institution's Research Bureau, on behalf of the FRQS, IRICoR and the Oncopole. The award letter will present the specific conditions of the award as well as the project plan, as approved/modified by the Committee. The Principal Investigator will then have no more than two (2) weeks to accept or reject the grant under the conditions set forth.

A funding agreement between IRICoR and the Competition awardee's managing Institution, aimed at covering the award, must also be signed before the funds are released.

If the conditions for releasing the funds allocated are not met (acceptance of the award by the Investigator and signing of the funding agreement) within three (3) months, IRICoR and the Oncopole, through the FRQS, reserve the right to cancel the award granted.

**Management of the award by Promoters and reporting**

As soon as the funds are released, an official project launch meeting will be set up between the research team and IRICoR.

Project follow-up will be ensured through meetings between IRICoR and the research team every four (4) months throughout the period of the award.

Annual scientific and financial progress reports must be completed within the agreed timelines.

After the 1<sup>st</sup> year of funding, if the project has not achieved the milestones expected, in keeping with the recommendations of the Committee, IRICoR and the Oncopole, through the FRQS, reserve the right, within one (1) month of receiving the report, to reduce or to terminate the funding granted for the 2<sup>nd</sup> year of the project.

Following approval of the reports by the Committee, 85% of the funds allocated for the second year of funding by IRICoR/FRQS/Oncopole will be paid.

When accepting the grant, the Principal Investigator agrees to provide, not more than three (3) months after the end of the grant, namely at the end of the two (2) years of funding, a final scientific report and a final financial report. If those 2 reports have not been received, the FRQS, IRICoR and the Oncopole reserve the right to withhold the final payment (the remaining 15% of the allocated funds).

Please note that Investigators who have been awarded funding in this Competition may benefit from IRICoR's established expertise in milestone-based project management and strategic oversight of intellectual property throughout the course of the funded project.

Moreover, projects having reached their milestones will benefit from access to IRICoR's business network thus facilitating their commercialization.

**Intellectual property (IP) and sharing of commercialization revenues**

There is no obligation to hold a patent or a patent application to file an application at this Competition.

The Background IP (BIP), including all know-how developed by an Institution and required for the project development will remain property of the Institution. IRICoR and all project participants (research teams and their Institutions of affiliation) will need to have access to that BIP for the sole purpose of the project's development.

As for the IP generated during the course of the project (Foreground IP (FIP)), the IP generated by the Institution where the Investigator(s) work(s) will be the property of that Institution and will be governed by the IP policy

	<p>that prevails in that Institution. IP generated by multiple Institutions will be considered as joint IP.</p> <p>Funding agreements between IRICoR and the Institution(s) involved will integrate each Institution’s IP policy and practices and will mandate IRICoR as a commercialization co-agent in collaboration with the technology transfer unit (or other equivalent entity) recognized by the Institution.</p> <p>IRICoR and the technology transfer unit (or equivalent entity) will be able to participate in the negotiation of exit events through potential partnerships with private entities, in line with CECR Program rules relating to benefits for Canada within initiatives towards IP commercialization.</p> <p>Terms of potential revenue sharing, between IRICoR and the Institutions involved, will be negotiated on a case-by-case basis according to the projects funded and will comply with the relevant regulations of the CECR Program Guide governing IRICoR funds.</p>
<p><b>Dissemination and use of the results by the Promoters</b></p>	<p>The grantees agree to authorize the Promoters to use reports and published research outputs that have been disseminated to the public by the Investigator(s) (as part of a scientific or electronic publication, of a conference, symposium or other) for reproduction, translation, execution or public communication purposes through any means, provided there is no infringement of copyright law.</p>
<p><b>Knowledge mobilization by Québec Investigators</b></p>	<p>The Promoters encourage awardees to participate in knowledge mobilization activities (transfer, sharing, development, promotion and dissemination) with relevant stakeholders, including the general public. For more details, please read the FRQ document “Knowledge Mobilization” in the toolbox.</p>

## APPLICANT’S AGREEMENT

In submitting his/her application, **the Investigator** must:

- Comply with regulations governing IRICoR’s activities, as outlined in the CECR Program Guide;
- Comply with the obligations outlined in the [Common General Rules](#), the [Policy Regarding Open Access to Published Research Outputs](#) of the FRQS as well as all the terms and conditions stipulated in the form and the Competition rules;
- Submit additional files related to the use of the grant, if requested by the FRQS, IRICoR or the Oncopole;
- Comply with the ethics and integrity standards outlined in the FRQS document [Standards en éthique de la recherche en santé humaine et d'intégrité scientifique](#) and in the [Policy for the Responsible Conduct of Research](#) of the *Fonds de recherche du Québec*;
- Authorize the FRQS, IRICoR and the Oncopole Executive Management Team to retain and use all personal and scientific information contained in the file, in keeping with the terms and conditions outlined in the document entitled [Protection of personal and scientific information – FRQS](#) (as set out in the Appendix to these Competition rules) and provided that individuals who are granted access to personal information respect its confidentiality.

## RESEARCH INSTITUTIONS AGREEMENT

The Institutions at which the research will be carried out agree to:

- Provide functional laboratories or research facilities as well as basic equipment required to carry out the research project;
- Offer an environment respectful of the ethics and integrity standards outlined in the FRQS document *Standards en éthique de la recherche en santé humaine et d'intégrité scientifique* and in the Policy for the Responsible Conduct of Research of the *Fonds de recherche du Québec*.

## TIMETABLE FOR THE EVALUATION PROCESS

Steps	Period	Dates
Competition launch	N/A	September 20, 2018
Deadline for submitting a notice of intent	6 weeks	October 30, 2018
Invitation to submit a complete application	4 weeks	November 27, 2018
Deadline for submitting a complete application	9 weeks	February 4, 2019
Evaluation by the Committee		March, 2019
Announcement of results		April, 2019

## APPENDIX A

### PROTECTION OF PERSONAL AND SCIENTIFIC INFORMATION

The forms completed under this Competition are intended to collect personal and scientific information about you. This information will be used and kept by the Fonds de recherche du Québec – Santé (FRQS). FRQS will confidentially share this information and evaluation reports with IRICoR and the Oncopole Executive Management Team (whose offices are located at Université de Montréal). The FRQS is subject to the *Act respecting Access to documents held by public bodies and the Protection of personal information* (CQLR, c. A-2.1) (Access Act). As a CEQR, IRICoR is governed by the following federal laws : i) *The Access to Information Act* et ii) *The Privacy Act* (link [here](#)).

FRQS will share the full applications as well as the financial and scientific reports to each Promoter of this Competition.

In this context, it is important to note that:

- The required personal and scientific information is used for the evaluation of grant applications, for the management of the Competition and allocated funds, and for the internal and external evaluation of the Competition. They are also used, aggregated with data from other candidates to generate statistics, inventories, evaluations and analyses related to the FRQS' mandate to promote and financially support health research.
- The information provided in these forms is mandatory for the analysis and evaluation of the grant applications. Failing to provide all the information required by the forms, the FRQS, the Oncopole and IRICoR will not be able to review the application.
- Individuals who have access to the information collected by the FRQS are members of the evaluation committees (including external experts), consultants, and authorized FRQS staff. Individuals who have access to this information commit to respect its confidentiality.
- The content of the forms, both personal information and research information, is confidential and is disclosed only in accordance with this Appendix, the [Énoncé relatif à la protection des renseignements personnels et confidentiels des dossiers des candidats, candidates et titulaires d'un octroi](#), with the consent of the data subject or the signatory of the application or in accordance with the provisions of the Access Act. with the consent of the person concerned or the person signing the application or in accordance with the provisions of the Access Act.
- Each individual has the right to access his/her personal information held by FRQS. He or she may require that any inaccurate, incomplete or equivocal personal information be modified. For further information on procedures for access, rectification or protection of personal information and access rights under the Access Act, the person responsible for Access Act to information at FRQS should be contacted.
- The three Fonds de recherche du Québec (Fonds de recherche du Québec – Nature et technologies, Fonds de recherche du Québec – Santé et Fonds de recherche du Québec – Société et culture) share their administrative services in accordance with the Act respecting the *Ministère de l'Enseignement supérieur, de la Recherche, de la Science et de la Technologie* (RLRQ, c. M-15.1.0.1). As a result, the FRQS may share the personal and scientific information provided on the forms with FRQNT and FRQSC staff whose collaboration is required to ensure optimal administration of funding competition and sound management of public funds.

For more information, please refer to the [Énoncé relatif à la protection des renseignements personnels et confidentiels des dossiers des candidats, candidates et titulaires d'un octroi](#).